Washington D.C.

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Amyloidosis3 trials
• High blood pressure3 trials
• Chronic kidney disease1 trial
• Metastatic breast cancer1 trial
• Myasthenia gravis1 trial
• Neuromyelitis optica (NMOSD)1 trial
• Obesity1 trial
• Sarcoidosis1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 23 trials
• Phase 33 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed4 trials
• Recruiting4 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Alnylam Pharmaceuticals7 trials
• Alexion Pharmaceuticals, Inc.2 trials
• Arvinas Estrogen Receptor, Inc.1 trial
• Priovant Therapeutics, Inc.1 trial

Running trials

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

  NCT06978725· Phase 2/3· Priovant Therapeutics, Inc.· Source

  Contact: Clinical Trial Administrator

• Active, not recruiting

  A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

  NCT06845202· Phase 1/2· Alnylam Pharmaceuticals· Source

• Enrolling by invitation

  A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

  NCT05966467· Alexion Pharmaceuticals, Inc.· Source

  Contact: Benjamin Osborne

• Recruiting

  Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

  NCT04202341· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Myasthenia gravis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Sarcoidosis1 recruiting

Closed trials

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

  NCT05501769· Phase 1· Arvinas Estrogen Receptor, Inc.· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

  NCT05103332· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

  NCT04936035· Phase 2· Alnylam Pharmaceuticals· Source